Sam Brusco, Associate Editor02.22.23
Teleflex has earned U.S. Food and Drug Administration (FDA) 510(k) clearance for its Triumph catheter and achieved first clinical use of its GuideLiner Coase catheter.
The Triumph catheter features six wire exit ports for precise wire advancement and clear visualization. It was designed in collaboration with Bill Nicholson, MD, Director of Interventional Cardiology at Emory Healthcare.
“In complex cases, the ability to better navigate tortuous anatomy has long been a challenge,” Dr. Nicholson told the press. “The Triumph Catheter’s nitinol ports and cage bring navigation and control to a new level, and I am excited that Teleflex will enable interventional cardiologists to readily access this important technology.”
The GuideLiner Coast catheter adds a hydrophilic option to Teleflex’s guide extension portfolio. It was was first used in a clinical procedure at the UW Medicine Heart Institute.
“Teleflex is committed to providing more options in the cath lab to help interventionalists address the specific needs of their patients,” said Scott Holstine, president and GM of Teleflex’s Interventional business unit. “The Triumph Catheter and the GuideLiner Coast Catheter reflect our focus on providing physicians with new choices and technologies engineered to address unmet clinical needs, personal preference and technique, and the challenges of complex anatomy.”
GuideLiner Coast is in limited market release currently, and full market release is expected later this year.
The Triumph catheter features six wire exit ports for precise wire advancement and clear visualization. It was designed in collaboration with Bill Nicholson, MD, Director of Interventional Cardiology at Emory Healthcare.
“In complex cases, the ability to better navigate tortuous anatomy has long been a challenge,” Dr. Nicholson told the press. “The Triumph Catheter’s nitinol ports and cage bring navigation and control to a new level, and I am excited that Teleflex will enable interventional cardiologists to readily access this important technology.”
The GuideLiner Coast catheter adds a hydrophilic option to Teleflex’s guide extension portfolio. It was was first used in a clinical procedure at the UW Medicine Heart Institute.
“Teleflex is committed to providing more options in the cath lab to help interventionalists address the specific needs of their patients,” said Scott Holstine, president and GM of Teleflex’s Interventional business unit. “The Triumph Catheter and the GuideLiner Coast Catheter reflect our focus on providing physicians with new choices and technologies engineered to address unmet clinical needs, personal preference and technique, and the challenges of complex anatomy.”
GuideLiner Coast is in limited market release currently, and full market release is expected later this year.